TRBC2-targeting antibody–drug conjugates for the treatment of T cell cancers
Jiaxin Ge(Howard Hughes Medical Institute), X. Li(Howard Hughes Medical Institute), Evangeline Watson(Howard Hughes Medical Institute), Kathy Gabrielson(Johns Hopkins University), Jacqueline Douglass(Howard Hughes Medical Institute), Sarah R. DiNapoli(Howard Hughes Medical Institute), Surojit Sur(Howard Hughes Medical Institute), Nickolas Papadopoulos(Johns Hopkins University), Maria Popoli(Johns Hopkins University), Maximilian F. Konig(Johns Hopkins Medicine), Charles G. Mullighan(St. Jude Children's Research Hospital), Nikita Marcou(Howard Hughes Medical Institute), Kenneth W. Kinzler(Johns Hopkins University), Brian J. Mog(Howard Hughes Medical Institute), Tushar D. Nichakawade(Howard Hughes Medical Institute), Cole Sterling(Sidney Kimmel Comprehensive Cancer Center), Chetan Bettegowda(Johns Hopkins University), J. David Peske(University of Virginia), Bert Vogelstein(Howard Hughes Medical Institute), Taha Ahmedna(Howard Hughes Medical Institute), Shibin Zhou(Cancer Genetics (United States)), Bum Seok Lee(Johns Hopkins University), Jin Liu(Howard Hughes Medical Institute), Joshua Urban(Howard Hughes Medical Institute), Richard F. Ambinder(Johns Hopkins University), Nina Wagner-Johnston(Johns Hopkins University), Steve Lu(Howard Hughes Medical Institute), Drew M. Pardoll(Johns Hopkins University), Stephanie Glavaris(Sidney Kimmel Comprehensive Cancer Center), Sima Rozati(Johns Hopkins University)
Cited by 1
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Cancer Genome Landscapes
|Science|2013|8k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k